Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

Supplementary Figure S3 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial

<p>Supplementary Figure 3. Forest plot with subgroup analysis for OS in substudy 1.</p>

محفوظ في:

التفاصيل البيبلوغرافية
المؤلف الرئيسي:	Fabrice Barlesi (15045504) (author)
مؤلفون آخرون:	Pascale Tomasini (4354063) (author), Maryam Karimi (7168769) (author), Stefan Michiels (108030) (author), Judith Raimbourg (15033410) (author), Catherine Daniel (7119086) (author), Henri Janicot (15019596) (author), Anne Madroszyk (15033398) (author), Clarisse Audigier-Valette (15045507) (author), Elisabeth Quoix (321740) (author), Julien Mazieres (15013412) (author), Denis Moro-Sibilot (15033407) (author), Eric Dansin (5576408) (author), Olivier Molinier (15019590) (author), Hugues Morel (15033419) (author), Eric Pichon (15033425) (author), Alexis Cortot (15045510) (author), Josiane Otto (6553544) (author), François Chomy (635983) (author), Pierre-Jean Souquet (3629372) (author), Nicolas Cloarec (15045513) (author), Etienne Giroux-Leprieur (385865) (author), Ivan Bieche (15045516) (author), Ludovic Lacroix (15030059) (author), Sandrine Boyault (9337805) (author), Valery Attignon (15045519) (author), Isabelle Soubeyran (515223) (author), Alain Morel (11665966) (author), Alicia Tran-Dien (14210462) (author), Alexandra Jacquet (14952799) (author), Filippo Gustavo Dall'Olio (15045522) (author), Marta Jimenez (14952288) (author), Jean-Charles Soria (15045525) (author), Benjamin Besse (3497516) (author)
منشور في:	2025
الموضوعات:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Clinical Trial Results Phase II clinical trials Drug Targets Immunotherapy Checkpoint blockade Lung Cancer Precision Medicine
الوسوم:	إضافة وسم لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!

مواد مشابهة

Supplementary Figure S1 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
حسب: Fabrice Barlesi (15045504)
منشور في: (2025)

Supplementary Figure S2 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
حسب: Fabrice Barlesi (15045504)
منشور في: (2025)

Supplementary Figure S4 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
حسب: Fabrice Barlesi (15045504)
منشور في: (2025)

Supplementary Figure S5 from Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung/IFCT 1301 Trial
حسب: Fabrice Barlesi (15045504)
منشور في: (2025)

Figure 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Figure 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Figure 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Table 1 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Table 2 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Table 3 from Combined Targeting of PD-1 and TIM-3 in Patients with Locally Advanced or Metastatic Non–Small Cell Lung Cancer: AMBER Part 2B
حسب: Diwakar Davar (15023480)
منشور في: (2025)

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
حسب: Robert W. Lentz (17013559)
منشور في: (2025)

Figure S1 from Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non–Small Cell Lung Cancer
حسب: Samuel Rosner (15054884)
منشور في: (2025)

Supplementary Tables 1 from A Phase II Trial of Guadecitabine plus Atezolizumab in Metastatic Urothelial Carcinoma Progressing after Initial Immune Checkpoint Inhibitor Therapy
حسب: H. Josh Jang (15206898)
منشور في: (2025)

Figure 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
حسب: Omid Hamid (15023912)
منشور في: (2025)

Figure 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
حسب: Omid Hamid (15023912)
منشور في: (2025)

Figure 3 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
حسب: Omid Hamid (15023912)
منشور في: (2025)

Table 1 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
حسب: Omid Hamid (15023912)
منشور في: (2025)

Table 2 from First-in-Human Phase I/II Study of INCAGN01876, a Glucocorticoid-Induced Tumor Necrosis Factor Receptor Agonist, in Patients with Advanced or Metastatic Solid Tumors
حسب: Omid Hamid (15023912)
منشور في: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
حسب: Roger Li (17078665)
منشور في: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
حسب: Dwight H. Owen (15034782)
منشور في: (2025)

Supplementary Figures1 from The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
حسب: Michael Michael (15021425)
منشور في: (2025)

Figure 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
حسب: Maria Alsina (21718246)
منشور في: (2025)

Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
حسب: Maria Alsina (21718246)
منشور في: (2025)

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
حسب: Maria Alsina (21718246)
منشور في: (2025)

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
حسب: Maria Alsina (21718246)
منشور في: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
حسب: Kohei Shitara (15043443)
منشور في: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
حسب: Kohei Shitara (15043443)
منشور في: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
حسب: Kohei Shitara (15043443)
منشور في: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
حسب: Kohei Shitara (15043443)
منشور في: (2025)